Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 RADIOACTIVE IODINE AS AN INDICATOR IN THYROID PHYSIOLOGY. V. THE USE OF RADIOACTIVE IODINE IN THE DIFFERENTIAL DIAGNOSIS OF TWO TYPES OF GRAVES' DISEASE.

Literature DB >> 16694888

RADIOACTIVE IODINE AS AN INDICATOR IN THYROID PHYSIOLOGY. V. THE USE OF RADIOACTIVE IODINE IN THE DIFFERENTIAL DIAGNOSIS OF TWO TYPES OF GRAVES' DISEASE.

S Hertz¹, A Roberts.

Abstract

Entities: Chemical Disease

Year: 1942 PMID： 16694888 PMCID： PMC435114 DOI： 10.1172/JCI101276

Source DB: PubMed Journal: J Clin Invest ISSN： 0021-9738 Impact factor: 14.808

× No keyword cloud information.

1 in total

1. RADIOACTIVE IODINE AS AN INDICATOR IN THYROID PHYSIOLOGY. IV. THE METABOLISM OF IODINE IN GRAVES' DISEASE.

Authors: S Hertz; A Roberts; W T Salter
Journal: J Clin Invest Date: 1942-01 Impact factor: 14.808

1 in total

13 in total

1. MEDICAL PROGRESS: ISOTOPES IN CLINICAL AND EXPERIMENTAL MEDICINE (Part I).

Authors: E C Dougherty; J H Lawrence
Journal: Calif Med Date: 1948-07

2. Nothing new under the nuclear sun: towards 80 years of theranostics in nuclear medicine.

Authors: Frederik A Verburg; Alexander Heinzel; Heribert Hänscheid; Felix M Mottaghy; Markus Luster; Luca Giovanella
Journal: Eur J Nucl Med Mol Imaging Date: 2013-11-06 Impact factor: 9.236

Review 3. Matched pairs dosimetry: 124I/131I metaiodobenzylguanidine and 124I/131I and 86Y/90Y antibodies.

Authors: Egesta Lopci; Arturo Chiti; Maria Rita Castellani; Giovanna Pepe; Lidija Antunovic; Stefano Fanti; Emilio Bombardieri
Journal: Eur J Nucl Med Mol Imaging Date: 2011-04-12 Impact factor: 9.236

4. Errare humanum est, sed in errare perseverare diabolicum: methodological errors in the assessment of the relationship between I-131 therapy and possible increases in the incidence of malignancies.

Authors: Frederik A Verburg; Martha Hoffmann; Ioannis Iakovou; Mark W Konijnenberg; Jasna Mihailovic; Pablo Minguez Gabina; Petra Petranović Ovčariček; Cristoph Reiners; Alexis Vrachimis; Slimane Zerdoud; Luca Giovanella; Markus Luster
Journal: Eur J Nucl Med Mol Imaging Date: 2020-03 Impact factor: 9.236

5. The early follow-up of 131I-treatment of thyrotoxicosis.

Authors: L N Daae; D M Solheim
Journal: Eur J Nucl Med Date: 1980-06

6. A study of the efficacy of radioiodine therapy with individualized dosimetry in Graves' disease: need to retarget the radiation committed dose to the thyroid.

Authors: M Schiavo; M C Bagnara; I Calamia; I Bossert; E Ceresola; F Massaro; M Giusti; A Pilot; G Pesce; M Caputo; M Bagnasco
Journal: J Endocrinol Invest Date: 2010-12-15 Impact factor: 4.256

RADIOACTIVE IODINE AS AN INDICATOR IN THYROID PHYSIOLOGY. V. THE USE OF RADIOACTIVE IODINE IN THE DIFFERENTIAL DIAGNOSIS OF TWO TYPES OF GRAVES' DISEASE.

1. RADIOACTIVE IODINE AS AN INDICATOR IN THYROID PHYSIOLOGY. IV. THE METABOLISM OF IODINE IN GRAVES' DISEASE.

1. MEDICAL PROGRESS: ISOTOPES IN CLINICAL AND EXPERIMENTAL MEDICINE (Part I).

2. Nothing new under the nuclear sun: towards 80 years of theranostics in nuclear medicine.

Review 3. Matched pairs dosimetry: 124I/131I metaiodobenzylguanidine and 124I/131I and 86Y/90Y antibodies.

4. Errare humanum est, sed in errare perseverare diabolicum: methodological errors in the assessment of the relationship between I-131 therapy and possible increases in the incidence of malignancies.

5. The early follow-up of 131I-treatment of thyrotoxicosis.

6. A study of the efficacy of radioiodine therapy with individualized dosimetry in Graves' disease: need to retarget the radiation committed dose to the thyroid.

Review 7. Radiotheranostics in Cancer Diagnosis and Management.

8. Highlights from endocrine surgical history.

9. Dose-response study on thyrotoxic patients undergoing positron emission tomography and radioiodine therapy.

10. Radiometabolic treatment of hyperthyroidism with a calculated dose of 131-iodine: results of one-year follow-up.